Key Takeaways
- Turnaround quarter, revenue milestone: Revenue crossed the historical ₹400 crores quarterly run rate, with management calling Q3 a turnaround that met most course-correction goals.
- Gross margin rebounded sharply: Gross margin improved 308 bps sequentially to 47.3%, driven by the course-correction strategy and reduced Vizag under-recovery as sales began.
- Vizag is now commercial, regulatory unlocks ahead: The site started manufacturing and selling intermediates and final APIs to semi-regulated markets, received Ibuprofen CEP approval, and has an EU inspection scheduled this quarter.
- Ibuprofen demand returned, China approval secured: Demand came back and returned inventory was sold; management stated Solara is probably the only company outside China with Ibuprofen approval for the China market.
- What to watch next quarter: Whether the EU inspection succeeds, whether Vizag sales ramp toward breakeven, and whether the gross margin inches closer to the 50% target as power and raw material costs normalize.
Turnaround & Financial Performance
- Revenue milestone: Crossed the historical ₹400 crores quarterly run rate, with base business showing strong growth momentum compared to the prior two quarters.
- Regulated markets lift: Contribution from regulated markets improved, aided by sales from the focus market Brazil.
- Gross margin jump: Improved 308 bps sequentially to 47.3%, attributed to the course-correction strategy yielding results and a reduction in Vizag under-recovery as commercial supplies began.
- Net current assets: Reduced by ₹42 crores in nine months, primarily from inventory reduction and GST refund follow-up.
- Working capital debt: Slight increase to support the sales uptick in Q3 and Q4.
- Pricing environment: Stable from a pricing point of view, with no substantial increase or decrease in raw material prices as per regular trend.
Jitesh Devendra: "Q3 FY'23 had been a turnaround quarter for Solara, as we have achieved most of the targeted goals when we embarked on the course correction journey last year."
Vizag Ramp-Up & Regulatory Pathway
- Commercial start: Began manufacturing intermediates and final APIs and made sales to semi-regulated markets during Q3; actions for Q3 sales were initiated in Q1 itself.
- Under-recovery shrinking: The start of sales to semi-regulated markets led to a reduction in under-recovery at the site.
- CEP approval secured: Received CEP approval for Ibuprofen on the Vizag site.
- EU inspection imminent: An EU inspection is scheduled in Q4, which management says will further enhance the ability to supply Ibuprofen from Vizag.
- US FDA wait: Management is waiting for a US FDA inspection triggered by a major customer, with no timeline offered.
- US DMF filed: One of the two new US DMFs filed in Q3 was filed from Vizag.
- Site qualification: Two critical products manufactured at Cuddalore were qualified at alternate sites, with Vizag and Pondy to be included as additional sites in the two product DMFs.
- Peak revenue potential: At full utilization, Vizag is expected to generate revenue of at least about ₹300-400 crores.
S. Hariharan: "Our immediate priority is to offset the under-recoveries at Vizag and achieve breakeven and profitable growth in the near-term."
Ibuprofen & Product Portfolio
- Demand recovery: Ibuprofen demand has come back; returned inventory was of good quality and has been sold, with no idle inventories sitting on the books.
- China market access: Management stated Solara is probably the only company outside of China that has obtained Ibuprofen approval for the China market.
- Value-added focus: The company is focusing on various forms of value-added Ibuprofen, which it expects will lead to gross margin expansion.
- Product disclosure limits: Management declined to provide Ibuprofen's quarterly revenue contribution or annual capacity, citing a policy of not breaking out individual product metrics.
- Market extensions: Five market extensions were completed for five existing products in Q3, with volume growth expected for critical products where extensions were done.
Jitesh Devendra: "We are probably the only company outside of China who has got the Ibuprofen approval for China market."
Cost Pressures & Margin Path
- Other expenses spike: A steep increase in power charges across manufacturing locations, plus normal inflation, drove the jump in other expenses; no one-time charge-off occurred during the quarter.
- Input cost drivers: Fuel briquettes (a major source), solvents, and other consumables saw price increases due to the international situation.
- Normalization expected: Power charges and consumables price increases are expected to regularize within one or two quarters; derivatives and metal prices have not yet come down in international markets.
- Gross margin ambition: The aspiration is to reach a minimum of 50%, with the ultimate aim to get back to FY21 levels of 56%; exact guidance is promised in the next investor call.
- Overall EBITDA target: Mid-to-high teens is what is being targeted for the company overall, taking into account Vizag and R&D costs.
Jitesh Devendra: "Our aspirations, of course, is to get to 50%. It is only about the timing as we firm up the business plans, and when do our CIP also come into play. So, we will have a better answer. But yes, the aspiration is to be at minimum 50%."
CRAMS, Filings & Growth Levers
- CRAMS leadership: Onboarded a CRAMS head for North America and made good inroads in the US market; traction from efforts is expected in the next financial year.
- RFP pipeline: Management is confident of winning some RFPs submitted in the first half of this year; CRAMS CAPEX will initially be more from an R&D perspective, not huge CAPEX, with commercial expansion possible if RFPs are won.
- US DMF cadence: Two new US DMFs filed in Q3; on track to file another four in Q4, bringing the full-year total to six new DMFs.
- Next-year pipeline: Four filings planned for Q4, with a pipeline of eight products for the next financial year.
- Geographic expansion: Looking to focus on Brazil and China where presence is marginal but opportunity is large, alongside other markets.
- Risk diversification: The stated goal is to derisk the product portfolio, dependence on customers, and dependence on markets.
- Backward integration: Unfinished backward integration projects remain on the agenda and are yet to be completed.
Jitesh Devendra: "But we are going to be very cognizant in terms of how we are going to invest in the CAPEX for the future growth of Solara."
Balance Sheet & Capital Allocation
- Debt reduction path: Once business operations improve, the company will slowly reduce debt to a comfortable level, targeting nearly three times EBITDA in the next financial year.
- Term loan repayment: ₹120 crores reduction per year is planned.
- CAPEX discipline: Only normal maintenance CAPEX was done during the current year, with capacities debottlenecked at the Vizag site; a long-term capital expenditure plan has not yet been firmed up and will be explained along with the growth strategy in the next call.
- Tax rate outlook: Net effective tax rate for FY24 is expected around 20%-22%.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue run rate | Maintain ₹400 crores quarterly run rate and get back to historical revenues | Ongoing |
| Gross margin | Reach minimum 50%, with aspiration to return to FY21 levels of 56% | Not dated (exact guidance promised next call) |
| US DMF filings | File four new DMFs in Q4, totaling six for FY23 | Q4 FY23 |
| Vizag EU inspection | EU inspection to enhance Ibuprofen supply capability from Vizag | Q4 FY23 |
| Vizag breakeven | Offset under-recoveries and achieve breakeven at Vizag | Near-term |
| Debt comfort | Reach nearly 3x EBITDA | Next financial year |
| Term loan repayment | ₹120 crores reduction per year | Annual |
| Tax rate | Net effective rate of 20%-22% | FY24 |
| New product pipeline | Eight products filed | Next financial year |
| Cost normalization | Power charges and consumables price increases to regularize | Within one to two quarters |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹401.9 cr, grew 17% sequentially |
| Gross margin | 47.3%, improved 308 bps sequentially |
| Operating EBITDA | ₹70 cr, 17.4% margin |
| Reported EBITDA | ₹51 cr, 12.7% margin, grew 70% sequentially |
| Base business EBITDA margin | 17.7% |
| Regulated market revenue share | 72% |
| Net current assets reduction (9M FY23) | ₹42 cr |
| Term loan outstanding | ₹352 cr, reduced from ₹414 cr at beginning of year |
| Annual term loan reduction plan | ₹120 cr per year |
| Target net debt-to-EBITDA | ~3x in the next financial year |
| Overall capacity utilization (excl. Vizag) | 77% |
| Ibuprofen utilization (Pondy facility) | ~90% |
| New US DMFs filed in Q3 | 2, one filed from Vizag |
| Market extensions in Q3 | 5 for 5 existing products |
| Total filings in Brazil | 4 |
| Vizag peak sales potential | ₹300-400 cr at full utilization |
| CRAMS revenue share | Single digit of overall company revenue |
| New product pipeline for next FY | 8 products |
| Net effective tax rate (FY24 outlook) | 20%-22% |